menu
    • menu
    [{"orgOrder":0,"company":"Nordic Bioscience","sponsor":"Bone Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"JTA-004","moa":"Adrenergic-alpha-2 receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Nordic Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nordic Bioscience \/ Nordic Bioscience","highestDevelopmentStatusID":"10","companyTruncated":"Nordic Bioscience \/ Nordic Bioscience"},{"orgOrder":0,"company":"Nordic Bioscience","sponsor":"Vivoryon Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Varoglutamstat","moa":"enzyme inhibitors","graph1":"Neurology","graph2":"Phase II","graph3":"Nordic Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nordic Bioscience \/ Nordic Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Bioscience \/ Nordic Bioscience"},{"orgOrder":0,"company":"Nordic Bioscience","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Sprifermin","moa":"growth factors: fibroblast growth factors","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Nordic Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nordic Bioscience \/ Nordic Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Bioscience \/ Nordic Bioscience"},{"orgOrder":0,"company":"Nordic Bioscience","sponsor":"Radius Health","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Abaloparatide","moa":"Parathyroid hormone receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Nordic Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Patch","sponsorNew":"Nordic Bioscience \/ Nordic Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"Nordic Bioscience \/ Nordic Bioscience"},{"orgOrder":0,"company":"Nordic Bioscience","sponsor":"KeyBioscience","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"KBP-042","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Nordic Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nordic Bioscience \/ Nordic Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Bioscience \/ Nordic Bioscience"},{"orgOrder":0,"company":"Nordic Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Puerarin","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Nordic Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Bioscience \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nordic Bioscience \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Nordic Bioscience

    Menu

    Nordic Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nordic Bioscience

                            Denmark arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nordic Bioscience

                            Denmark arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : Vivoryon Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerat...

                            Details : Varoglutamstat (PQ912) is a differentiated oral small-molecule targeting the toxic Abeta species N3pE which is being developed as disease-modifying therapy and is designed to target AD pathology upstream of Abeta-antibody focused approaches.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 31, 2022

                            Lead Product(s) : Varoglutamstat

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : Vivoryon Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nordic Bioscience

                            Denmark arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nordic Bioscience

                            Denmark arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Puerarin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Finding Evaluation of Kudzu Root Extract in Women With Menopause Symptoms

                            Details : Kudzu Root Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Menopause.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            September 17, 2020

                            Lead Product(s) : Puerarin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nordic Bioscience

                            Denmark arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nordic Bioscience

                            Denmark arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JTA-004

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Recipient : Bone Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomati...

                            Details : JTA-004 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 03, 2020

                            Lead Product(s) : JTA-004

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Recipient : Bone Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nordic Bioscience

                            Denmark arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nordic Bioscience

                            Denmark arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KBP-042

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Recipient : KeyBioscience

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes

                            Details : KBP-042 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 26, 2017

                            Lead Product(s) : KBP-042

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Recipient : KeyBioscience

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nordic Bioscience

                            Denmark arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nordic Bioscience

                            Denmark arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sprifermin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Recipient : EMD Serono

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Oste...

                            Details : Sprifermin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 08, 2013

                            Lead Product(s) : Sprifermin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Recipient : EMD Serono

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nordic Bioscience

                            Denmark arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed

                            Nordic Bioscience

                            Denmark arrow
                            Indonesia Pharmaceutical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abaloparatide

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Recipient : Radius Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

                            Details : Abaloparatide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteoporosis, Postmenopausal.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 29, 2012

                            Lead Product(s) : Abaloparatide

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Recipient : Radius Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth